Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.

Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be red...

Descripción completa

Detalles Bibliográficos
Autores principales: Keeling, A. A., Vaughan, A. T., Beaney, R. P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247361/
https://www.ncbi.nlm.nih.gov/pubmed/2803919
_version_ 1782150965720252416
author Keeling, A. A.
Vaughan, A. T.
Beaney, R. P.
author_facet Keeling, A. A.
Vaughan, A. T.
Beaney, R. P.
author_sort Keeling, A. A.
collection PubMed
description Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.
format Text
id pubmed-2247361
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22473612009-09-10 Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias. Keeling, A. A. Vaughan, A. T. Beaney, R. P. Br J Cancer Research Article Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72 h, but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity. Nature Publishing Group 1989-07 /pmc/articles/PMC2247361/ /pubmed/2803919 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Keeling, A. A.
Vaughan, A. T.
Beaney, R. P.
Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title_full Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title_fullStr Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title_full_unstemmed Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title_short Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
title_sort yttrium-90-edtmp: a radiotherapeutic agent in the treatment of leukaemias.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247361/
https://www.ncbi.nlm.nih.gov/pubmed/2803919
work_keys_str_mv AT keelingaa yttrium90edtmparadiotherapeuticagentinthetreatmentofleukaemias
AT vaughanat yttrium90edtmparadiotherapeuticagentinthetreatmentofleukaemias
AT beaneyrp yttrium90edtmparadiotherapeuticagentinthetreatmentofleukaemias

Ejemplares similares